Outcomes of Stent-Assisted Coiling Using the Neuroform Atlas Stent in Unruptured Wide-Necked Intracranial Aneurysms by 권오혁 & 정준호
23Copyright © 2021 The Korean Neurosurgical Society 
Clinical Article
J Korean Neurosurg Soc 64 (1) : 23-29, 2021
https://doi.org/10.3340/jkns.2020.0054 pISSN 2005-3711   eISSN 1598-7876
Outcomes of Stent-Assisted Coiling Using the Neuroform  
Atlas Stent in Unruptured Wide-Necked Intracranial Aneurysms
Ohyuk Kwon, Joonho Chung
Department of Neurosurgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Objective : Although stent-assisted coiling (SAC) has been reported to be safe and effective in treating wide-necked aneurysms, 
the technique has procedure-related complications. Thus, we reported our experiences of SAC using the Neuroform Atlas stent in 
treating wide-necked aneurysms and evaluated the incidence of and risk factors for procedure-related complications.
Methods : From March 2018 to August 2019, we treated 130 unruptured wide-necked aneurysms in 123 patients with Neuroform 
Atlas stents. Angiographic results and clinical outcomes were reviewed retrospectively. Clinical and angiographic follow-up were 
performed in all cases (mean, 12.4 months) after the procedure.
Results : There were eight cases (6.2%) of procedure-related complications (two dissections, five thromboembolisms, and one 
hemorrhage) and two (1.5%) of delayed complications (one ischemia and one hemorrhage). There was one case (0.8%) of failure of 
stent deployment and one (0.8%) of suboptimal positioning of the stent. Follow-up angiography showed complete obliteration in 
103 (79.2%), residual neck in 16 (12.3%), and residual aneurysm in 11 cases (8.5%). Aneurysm locations in the middle cerebral artery 
(odds ratio [OR], 2.211; p=0.046) and the anterior communicating artery (OR, 2.850; p=0.039) were associated with procedure-
related complications on univariate analysis. However, no independent risk factor for procedure-related complications was noted in 
multivariate analysis.
Conclusion : The Neuroform Atlas showed a high rate of technical success. Good clinical and radiographic outcomes in early 
follow-up suggests that the device is feasible and safe. SAC of aneurysms on the middle cerebral artery or anterior communicating 
artery may require more attention to prevent possible procedure-related complications.
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INTRODUCTION
It is well established that wide-necked intracranial aneu-
rysms are difficult to treat endovascularly due to the risk of 
coil protrusion in the parent artery and aneurysm recurrence. 
Stent-assisted coiling (SAC) has been established as one of the 
treatment options for these endovascularly challenging aneu-
rysms, thereby improving the results. Intracranial stents allow 
the reconstruction of the aneurysm neck and help maintain 
the coil mass within the aneurysm sac. Recently, the Neuro-
form Atlas stent (Stryker Neurovascular, Kalamazoo, MI, 
USA), a microcatheter-delivered, self-expanding, mixed open-
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cell/closed-cell stent, has been used widely. With low-profiled, 
easy handling deliveries, the Neuroform Atlas stent is being 
widely applied for wide-necked intracranial aneurysms in 
various ways9,12).
Although SAC using the Neuroform Atlas stent has been 
reported to be safe and effective in treating wide-necked an-
eurysms1,6,7,13,14), the technique has procedure-related compli-
cations that interventionists need to understand completely. 
However, none of those studies reported the incidence of and 
risk factors for procedure-related complications. Thus, this 
study aimed to report our experience with SAC using the 
Neuroform Atlas stent in treating unruptured wide-necked 
aneurysms and to evaluate the incidence of and risk factors 
for procedure-related complications.
MATERIALS AND METHODS 
Patient selection
This retrospective study was approved by Yonsei University 
Health System, Severance Hospital, Institutional Review 
Board (4-2020-0573), and the requirement for informed con-
sent was waived. The Neuroform Atlas was approved for use 
in our country in March 2018. From March 2018 to August 
2019, we treated 435 aneurysms (367 unruptured and 68 rup-
tured) in 381 patients endovascularly. Among 214 aneurysms 
treated with SAC, 130 unruptured wide-necked aneurysms in 
123 patients were treated with Neuroform Atlas stents. Among 
the 68 ruptured aneurysms cases during the same period, we 
tried to perform endovascular treatment other than the use of 
stents considering our results pertaining to SAC for ruptured 
aneurysms3).
Aneurysm size and morphological characteristics were deter-
mined using digital subtraction angiography with 3D rotational 
imaging. A wide-necked saccular aneurysm was defined as that 
with a dome-to-neck ratio of <2 or a neck diameter of ≥4 mm. 
Thromboembolic complications were defined as angiographic 
evidence of thrombosis during or at the end of SAC. Asymp-
tomatic post-operative small diffusion restrictions on diffusion 
weighted image were not regarded as thromboembolic compli-
cations. Hemorrhagic complications were defined as newly de-
veloped hemorrhage on computed tomography (CT) or mag-
netic resonance image within 30 days of the procedure. The 
incidence of and risk factors for procedure-related complica-
tions were retrospectively evaluated.
Endovascular treatment 
The treatment decision was made based on agreement be-
tween microvascular neurosurgeons and neuro-intervention-
ists. All SAC procedures were performed under general anes-
thesia. A 5-Fr to 7-Fr guiding catheter was positioned in the 
internal carotid artery for anterior circulation aneurysms. A 
5-Fr or 6-Fr guiding catheter was positioned in the vertebral 
artery for posterior circulation aneurysms. Intravenous sys-
temic heparin (50 U/kg) was administered while placing the 
guiding catheter. An activated clotting time of 2–2.5 times 
that of baseline was maintained during endovascular treat-
ment. An Excelsior SL-10 (Stryker Neurovascular) was used to 
deliver the Neuroform Atlas stent. The jailing or semi-jailing 
techniques were primarily performed, and if these failed, the 
through the strut (cell-through) technique was im plemented.
Patients were administered a daily dose of clopidogrel 75 mg 
and aspirin 100 mg for more than 7 days before the SAC pro-
cedure. For patients with insufficient premedication or when 
the SAC was planned immediately after the diagnostic digital 
subtraction angiography, a loading dose of aspirin and clopi-
dogrel of 300 mg each was administered the day before treat-
ment. Platelet function testing was routinely performed for all 
patients. After the procedure, patients were prescribed 75 mg 
of clopidogrel daily for 3 months and 100 mg of aspirin daily 
for at least 12 months. Magnetic resonance imaging was rou-
tinely performed within 24 hours after SAC for all patients 
and included diffusion-weighted imaging, T2-weighted imag-
ing, f luid-attenuated inversion recovery, and gradient echo 
imaging. 
Clinical and radiographic outcomes
Angiographic results and clinical outcomes were reviewed 
retrospectively. Clinical and angiographic follow-up was per-
formed in all 123 patients with 130 aneurysms between 3 and 
20 months (mean, 12.4 months) after the procedure. The an-
giographic results were evaluated by two independent investi-
gators and categorized as complete occlusion (without a neck 
remnant), neck remnant (>90% occlusion with small neck 
remnant or dog ear), or partial occlusion (filling of the aneu-
rysm lumen). Clinical outcomes were assessed using the mod-
ified Rankin Scale and evaluated at the time of discharge and 
out-patient follow-up by an independent investigator who was 
  SAC with the Neuroform Atlas | Kwon O, et al.
25J Korean Neurosurg Soc 64 (1) : 23-29
not involved in patient care.
Statistical analysis 
All statistical analyses were performed after consulting with 
a biostatistician using R language ver. 3.01 (R Foundation for 
Statistical Computing, Vienna, Austria). Student’s t-tests were 
used for numeric variables. Chi-square tests were used for 
nominal variables. Logistic regression analysis was performed 
to determine the independent risk factors for procedure-relat-
ed complications. Multiple logistic regression analyses were 
performed for variables with an unadjusted effect and with a 
p value <0.10 in simple logistic regression analysis. The 95% 
confidence interval (CI) was calculated for all p values, which 
were considered statistically significant at <0.05.
RESULTS
Baseline demographics and aneurysm characteristics are 
summarized in Table 1. Of the 123 patients included in this 
study, there were 96 women, and the median age was 60.2 
years (range from 29 to 79). Patient baseline characteristics in-
cluded hypertension in 63 patients (51.2%), diabetes in 29 
(23.6%), smoking history in 19 (15.4%), dyslipidemia in 16 
(13.0%), and coronary heart diseases in 11 (8.9%). Aneurysms 
were located in the internal carotid artery in 65 cases (50.0%), 
posterior communicating artery in nine (6.9%), middle cere-
bral artery in 18 (13.8%), anterior communicating artery in 17 
(13.1%), anterior cerebral artery in 10 (7.7%), basilar artery in 
nine (6.9%), and vertebral artery in two (1.5%). The mean an-
eurysm size was 5.3±1.7 mm, and the mean neck size was 3.9±
0.8 mm.
Table 2 shows the clinical and radiographic outcomes of the 
aneurysms. In terms of technical considerations, there was 
one case (0.8%) of failure of stent deployment and one (0.8%) 
of suboptimal positioning of the stent. These two events hap-









Coronary heart disease 11 (8.9)
Aneurysm 130
Aneurysm size (mm) 5.3±1.7
Neck size (mm) 3.9±0.8
Aneurysm location
Internal carotid artery 65 (50.0)
Posterior communicating artery 9 (6.9)
Middle cerebral artery 18 (13.8)
Anterior communicating artery 17 (13.1)
Anterior cerebral artery 10 (7.7)
Basilar artery 9 (6.9)
Vertebral artery 2 (1.5)
Values are presented as mean±standard deviation or number (%)
Table 2. Clinical and radiographic outcomes of the aneurysms
Value (n=130)
Technical considerations
Deployment failure 1 (0.8)
Suboptimal positioning 1 (0.8)
Y-stenting 3 (2.3)
Stent salvage 6 (4.6)
Initial angiographic results
Complete obliteration 61 (46.9)
Residual neck 44 (33.8)
Residual aneurysm 25 (19.2)
Follow-up angiographic results
Complete obliteration 103 (79.2)
Residual neck 16 (12.3)
Residual aneurysm 11 (8.5)








Morbidity (mRS 1–5) 0 (0.0)
Mortality 0 (0.0)
mRS : modified Rankin Scale
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pened because the delivery microcatheters suddenly dropped 
to the proximal part of very tortuous internal carotid arteries. 
We performed Y-stenting (Atlas-Atlas; Stryker Neurovascular, 
Fremont, CA, USA) in three patients (2.3%) and stent salvage 
in six (4.6%). Immediate postembolization angiographic re-
sults showed complete obliteration in 61 aneurysms (46.9%), 
residual neck in 44 (33.8%), and residual aneurysm in 25 
(19.2%). Follow-up angiographic results were obtained in all 
aneurysms and showed complete obliteration in 103 (79.2%), 
residual neck in 16 (12.3%), and residual aneurysm in 11 
(8.5%). There was no recurrence of the aneurysm during the 
follow-up period. With respect to clinical outcomes, there 
were no morbidity or mortality cases even though there were 
eight cases (6.2%) of procedure-related complications (two 
dissections, five thromboembolisms, and one hemorrhage) 
and two (1.5%) of delayed complications (one ischemia and 
one hemorrhage). All five patients with thromboembolic com-
plications underwent intra-arterial thrombolysis in which a 
glycoprotein IIb/IIIa antagonist (tirofiban) was used and 
showed successful recanalization without any symptoms. Two 
patients experienced vertebral artery dissection due to guiding 
catheter placement and were treated conservatively.
Logistic regression analysis was used to determine indepen-
dent associations of procedure-related complications with other 
factors. On univariate analysis, aneurysm locations in the mid-
dle cerebral artery (odds ratio [OR], 2.211; 95% CI, 1.196–3.993; 





Yes (n=8) No (n=122) OR (95% CI) p-value OR (95% CI) p-value
Age (years) 59.0±10.4 60.3±9.9 1.094 (0.944–1.326) 0.823 0.975 (0.962–1.149) 0.652 
Sex
Female (n=102) 6 (75.0) 96 (78.7) 1
Male (n=28) 2 (25.0) 26 (21.3) 1.085 (0.517–2.023) 0.575 1.029 (0.554–1.898) 0.711 
Hypertension, yes 6 (75.0) 62 (50.8) 2.616 (0.828–9.205) 0.138 
Diabetes, yes 2 (25.0) 27 (22.1) 1.312 (0.750–3.206) 0.676 
Smoking, yes 1 (12.5) 18 (14.8) 0.816 (0.471–3.054) 0.765 
Dyslipidemia, yes 0 (0.0) 16 (13.1) 0.625 (0.433–5.224) 0.218 
Coronary heart disease, yes 0 (0.0) 11 (8.5) 0.687 (0.682–3.469) 0.270 
Aneurysm location
Internal carotid artery (n=65) 1 (12.5) 64 (52.5) 1
Posterior communicating artery (n=9) 0 (0.0) 9 (7.4) 0.972 (0.300–2.832) 0.442 
Middle cerebral artery (n=18) 3 (37.5) 15 (12.3) 2.211 (1.196–3.993) 0.046 1.525 (0.943–3.021) 0.088 
Anterior communicating artery (n=17) 3 (37.5) 14 (11.5) 2.850 (1.298–5.143) 0.039 2.559 (0.954–4.622) 0.067 
Anterior cerebral artery (n=10) 0 (0.0) 10 (8.2) 0.575 (0.447–1.866) 0.385 
Basilar artery (n=9) 1 (12.5) 8 (6.6) 0.727 (0.486–1.978) 0.524 
Vertebral artery (n=2) 0 (0.0) 2 (1.6) 0.922 (0.907–1.054) 0.810 
Aneurysm neck
Relative wide neck (<4 mm, n=76) 6 (75.0) 70 (57.4) 1
Absolute wide neck (≥4 mm, n=54) 2 (25.0) 52 (42.6) 0.922 (0.668–3.218) 0.186 
Aneurysm size
Small (<5 mm, n=64) 5 (62.5) 59 (48.4) 1
Medium (<10 mm, n=59) 3 (37.5) 56 (45.9) 0.750 (0.638–2.169) 0.302 
Large (≥10 mm, n=7) 0 (0.0) 7 (5.7) 0.332 (0.305–1.811) 0.489 
Values are presented as mean±standard deviation or number (%) unless otherwise indicated. OR : odds ratio, CI : confidence interval
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p=0.046) and the anterior communicating artery (OR, 2.850; 
95% CI, 1.298–5.143; p=0.039) was associated with procedure-
related complications (Table 3). However, no independent risk 
factor for procedure-related complications was noted in the 
multivariate logistic regression analysis adjusted for age and sex. 
DISCUSSION
In the present study, the procedure-related complication 
rate was 6.2% among 123 patients with 130 unruptured wide-
necked aneurysms. Further, no case of morbidity/mortality 
was noted with SAC for unruptured wide-necked intracranial 
aneurysms with the Neuroform Atlas. Thromboembolic com-
plications were the most common at 3.8% followed by dissec-
tion (1.5%) and hemorrhage (0.8%). The technical success rate 
of delivering and deploying the stent was 98.5% among the 
130 cases. Delayed ischemia due to transient ischemic attack 
and a small amount of delayed hemorrhage in the left frontal 
lobe occurred in one case each during the follow-up period, 
with both patients being asymptomatic. We found that stent 
deployment in the middle cerebral artery and anterior com-
municating artery was associated with procedure-related 
complications in the univariate analysis.
An expected benefit of the Neuroform Atlas stent is its in-
creased navigability, which allows easy delivery12). The Neuro-
form Atlas stent is the latest version of the Neuroform series 
with reinforced navigability within a smaller microcatheter 
that confers stability to the vessel wall (high radial force), en-
ables accurate placement (ease of use with very low foreshort-
ening), and allows wall apposition, conformability, and coil 
protection. It can be delivered via a 0.0165-inch microcatheter, 
the smallest profile, allowing neurointerventionists to per-
form SAC without difficulty. The cell size of the Neuroform 
Atlas stent is smaller compared to that of its predecessor, the 
Neuroform stent. This enables better coil protection in aneu-
rysms and allows the use of smaller coils. Additionally, the 
width of the struts has been reduced to improve flexibility and 
conformability of the stent. Furthermore, the segmental open-
ing of the struts allows stable positioning and direct vessel wall 
apposition by anchoring the stent after the first rows of the 
struts exit the microcatheter. These characteristics of the Neu-
roform Atlas make SAC safer and more effective.
There have been a few reports on SAC with Neuroform At-
las stents, of which most have reported that SAC using Neuro-
form Atlas stents is safe and effective in treating wide-necked 
aneurysms1,6,7,13,14). From their experience with 27 consecutive 
patients, the authors of one study concluded that Neuroform 
Atlas SAC is feasible for treating ruptured and unruptured 
wide-necked aneurysms that are not amenable to convention-
al coiling or clipping13). The aneurysm occlusion and favorable 
clinical outcomes were consistent with those previously re-
ported for SAC of wide-neck aneurysms using other devices13). 
These previous authors reported favorable and complete oc-
clusion rates of 69.2% and 53.8% at 6 months, respectively. 
Another report concluded that deployment of the Neuroform 
Atlas stent was a safe and effective method for the treatment 
of wide-necked aneurysms from their experiences with 37 an-
eurysms in 36 patients14). They reported satisfactory immedi-
ate angiographic outcomes : complete aneurysm obliteration 
was observed in 84% cases, while neck remnants were ob-
served in the remaining 16%. Furthermore, high-resolution 
time-of-f light magnetic resonance angiography revealed an 
occlusion rate of 100% at the 5-month follow-up. Additionally, 
other reports showed a complete occlusion rate of 86.7% with 
the Neuroform Atlas system6). The complete occlusion rate of 
79.2% in the present study is in accordance with the results 
published previously, highlighting the efficacy of the Neuro-
form Atlas.
Compared to the Low-profile Visualized Intraluminal Sup-
port Junior device (LVIS Jr; MicroVention, Tustin, CA, USA), 
the Neuroform Atlas is less visible because only the stent 
markers at each end of the stent are radiopaque, although the 
struts themselves are invisible. Nevertheless, the visibility of 
the Neuroform Atlas was sufficient to allow accurate place-
ment and deployment of the device in the present study. Ad-
ditionally, the high outward radial force of the Neuroform At-
las ensures opening and wall apposition of the stent. If the 
complete opening of the stent is doubtful, the struts can be vi-
sualized by unenhanced f lat-panel detector CT13). This ap-
proach can be employed to overcome the disadvantage of the 
open-cell design of the Neuroform Atlas stent, which causes 
resheathing after its deployment difficult. However, neuroin-
terventionists should be aware of the possibility of delivery 
microcatheters unexpectedly falling down in tortuous parent 
arteries for the optimal deployment of the stent. According to 
the thromboembolic complications, it seems that there is no 
difference in the rate of thromboembolic complications be-
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tween Neuroform Atlas and LVIS stents. We reported 6.5% of 
thromboembolic complications using Neuroform Atlas stents, 
whereas LVIS family (LVIS and LVIS Jr) had 3.6–5.8%2,5,15). 
However, intra-procedural thromboembolic complications 
occurred in 8% among 25 patients in SAC of anterior com-
municating artery aneurysms using the LVIS Jr stent10), sup-
porting our result of possible higher rate of procedure-related 
complications in the parent arteries with small diameter, such 
as middle cerebral artery or anterior communicating artery. 
Another report showed that a series of 100 patients treated 
with the LVIS Jr stent with thromboembolic complications 
occurring in 14% of the cases and concluded that the poten-
tially inadequate antiplatelet response and use of the stent it-
self are possible reasons for thromboembolic phenomena in 
patients with acutely ruptured aneurysms11). 
With increasing clinical experience and development of 
new devices, SAC of aneurysms with a small parent artery has 
been known to be feasible in selected cases and show good 
long-term patency rates of parent arteries4,8,16,17). Regardless of 
the stent type (open-cell or closed-cell), the deployment of 
stents in small arteries, such as anterior cerebral arteries, mid-
dle cerebral arteries, posterior cerebral arteries, or posterior 
inferior cerebellar arteries, was safe and resulted in good pa-
tency. Nevertheless, the possibility of thromboembolic com-
plications and parent artery occlusion should not be neglected 
when performing SAC of aneurysms with a small parent ar-
tery. In the present study, no independent risk factors for pro-
cedure-related complications could be determined through a 
multivariate logistic regression analysis adjusted for age and 
sex. However, SAC of aneurysms located in the middle cere-
bral artery or anterior communicating artery showed an asso-
ciation with procedure-related complications in univariate 
analysis. Thus, using the Neuroform Atlas in distal small par-
ent arteries might be feasible, although its possible procedure-
related complications should be considered. 
Stents with an open-cell design show better wall apposition 
in tortuous vessels compared with closed-cell stents. However, 
incomplete stent apposition is more likely to be found in small 
arteries with tortuous anatomy. In addition, the low radial 
force of stents could be one cause of poor wall apposition. Al-
though poor wall apposition may improve by open-cell stents, 
it might not work properly in a small-sized tortuous parent 
artery. The stent might not fully deploy in small arteries with 
acute angles because of kinking, twisting, or ovalization at the 
angles. This is especially concerning in arteries with a small 
diameter. Furthermore, increased metal surface coverage 
might increase the risk of thromboembolism when stents are 
deployed in small arteries. Thus, it can’t be too careful of per-
forming SAC in the parent artery with small diameter, such as 
anterior cerebral artery or middle cerebral artery.
The present study had several limitations including the ret-
rospective data collection and the small number of patients 
with an unruptured aneurysm enrolled, and thus, the effects 
of possible selection bias cannot be excluded. Moreover, as the 
follow-up period was short (less than 2 years), longer follow-
up is needed to assess the stability of adequate obliteration. 
Furthermore, there was no true control group for the evalua-
tion of the efficacy and safety of the device. Thus, compari-
sons with different devices and laboratory experiments to im-
prove the technical defects of the Neuroform Atlas should be 
performed in additional clinical trials.
CONCLUSION 
The Neuroform Atlas stent showed a high rate of technical 
success with good navigability. Good clinical and radiograph-
ic outcomes in early follow-up suggest that the device is safe 
and reliable with minimal risks for SAC of unruptured intra-
cranial aneurysms in both anterior and posterior circulation. 
In cases of SAC of unruptured intracranial aneurysms in the 
middle cerebral artery or anterior communicating artery, 
more careful use of the Neuroform Atlas may be required to 
prevent possible procedure-related complications. Large co-
hort studies with a longer follow-up are necessary to deter-
mine the long-term durability and safety of the device as well 
as the risk factors for procedure-related complications.
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